Short-acting Beta Agonists Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
- Cipla Inc.
- Merck & Co., Inc.
- Schering-Plough Corporation
- AstraZeneca
- Johnson & Johnson Services, Inc.
Bayer AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of short-acting beta agonists is assessed at USD 940.69 million.
The global short-acting beta agonists market size was valued at over USD 868.04 million in 2025 and is expected to expand at a CAGR of around 9.3%, surpassing USD 2.11 billion revenue by 2035.
North America is anticipated to secure a 42% share by 2035 in the short-acting beta agonists market, bolstered by the presence of major industry players.
Key players in the market include Teva Pharmaceutical Industries Ltd., Viatris Inc., F.Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Cipla Inc., Merck & Co., Inc., Schering-Plough Corporation, AstraZeneca, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited.
